A型肉毒毒素泪腺注射抑制泪液分泌临床应用的研究现状

Current clinical application of lacrimal gland injection of botulinum toxin type A in inhibiting lacrimal secretion

泪腺注射A型肉毒毒素(BTXA)抑制泪液分泌,作为一种新的治疗或缓解流泪或溢泪症状的方法,具有操作简单,疗效确切,可重复治疗,无不可逆的并发症等特点,为许多难治性流泪或溢泪的患者提供一种可选择的治疗方案。本文对BTXA的药理学特征和抑制泪液分泌的机制、泪腺注射的方法及剂量、适应证和禁忌证、临床疗效评价、并发症、目前存在的尚待解决的问题及前景展望等进行综述。

Lacrimal gland injection of botulinum toxin type A inhibits the secretion of tears.As a new method to treat or alleviate the symptom of tears or epiphora,it has the characteristics of simple operation,definite curative effect,repeatable treatment and no irreversible complications.It provides an optional treatment scheme for many patients with refractory tears or epiphora.This article reviews the pharmacological characteristics of botulinum toxin type A,the mechanism of inhibiting tear secretion,the method and dose of lacrimal gland injection,indications and contraindications,clinical efficacy evaluation,complications,existing problems to be solved and prospects for reference.